95 % Beta-Ecdysterone
Derived from the root of Cyanotis arachnoidea, this ultra-pure extract is The Extract Factory’s signature ingredient. Raw-material harvesting is richest from September through October, yet global purchasing surges between April and May. That predictable lag can tighten supply and push prices upward. We bridge the gap by stockpiling at harvest and releasing inventory year-round, giving buyers fixed-cost security and uninterrupted availability.

SUPPLY-CHAIN STRATEGY
Our demand-forecast model aligns agricultural output with forward purchase orders. Material collected during the two-month harvest window is promptly processed, quarantined, and warehoused under nitrogen flush and 15 °C conditions. The result: no back-orders, no price spikes, and batch-to-batch consistency you can schedule your production around.

LATIN NAME: Cyanotis arachnoidea C.B. Clarke
ACTIVE CONSTITUENT: 20-Hydroxyecdysterone (≥ 95 %)
PLANT PART: Tuber & fibrous root
HEAVY METALS: ≤ 10 mg kg
TOTAL PLATE COUNT: ≤ 1 000 CFU g
PARTICLE SIZE: ≥ 95 % pass 80 mesh

WHY THE EXTRACT FACTORY?

  1. Verified Purity: Every lot is triple-screened for potency, heavy-metal residues, solvent traces, and microbial limits. Certificates of Analysis accompany each drum.

  2. Ongoing R&D: Our in-house lab collaborates with European universities to refine isolation protocols and explore new delivery formats—micro-encapsulated, water-dispersible, and nano-emulsified versions are already in pilot scale.

  3. Worldwide Logistics: From Rotterdam to Los Angeles to Bangkok, we ship under temperature-controlled conditions and provide all import documentation (COA, SDS, GMO-free, allergen, and irradiation statements).


KEY APPLICATIONS

  1. Lean-Muscle Support: Peer-reviewed trials report enhanced MPS (muscle-protein synthesis) without androgenic side-effects, making 95 % beta-ecdysterone a sought-after sports-nutrition active.

  2. Skeletal Health: The compound up-regulates osteoblast ALP activity while suppressing RANKL-mediated osteoclastogenesis, offering dual action for bone-formulation supplements.

  3. Neuroprotection: Pre-clinical data suggest modulation of MAPK/ERK signaling reduces β-amyloid cytotoxicity, positioning beta-ecdysterone as a promising nootropic research agent.


Secure your annual requirement at a locked price. Email [email protected] for specification sheets, stability data, and a quotation tailored to your volume.

FacebookXEmailLinkedIn